- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01718808
Cetuximab for Elderly Patients With mCRC
Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary endpoint: If in a treatment arm the number of patients alive and without progression at 12 weeks is 17 or more, this arm will be considered promising, otherwise not promising. Additionally, a two-sided 95% confidence interval for the difference in Progression free survival (PFS) rates between the two arms will be calculated.
Secondary endpoints and patient characteristics:
- Laboratory values may be expressed as the absolute values (continuous variables) or/and as grading (ordinal categorical variables).
- Generally for each categorical variable the results will be summarized by frequencies and percentages. For response rates 95% Clopper-Pearson confidence intervals will be calculated.
- For each adverse event, the results will be summarized by frequencies and percentages of different grades among all cycles as well as by frequencies and percentages of the within-patient worst grades
- For each continuous variable the results will be summarized by descriptive statistics.
- Time-to-event variables will be presented by Kaplan-Meier curves and summarized by medians and 95% confidence intervals.
- All analysis will be done by treatment arm.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, CH-4031
- Universitaetsspital-Basel
-
Bern, Switzerland, CH-3010
- Inselspital, Bern
-
Biel, Switzerland, CH-2501
- Spitalzentrum Biel
-
Fribourg, Switzerland, 1708
- Hôpital Fribourgeois
-
Geneva, Switzerland, CH-1211
- Hopital Cantonal Universitaire de Geneve
-
Lausanne, Switzerland, CH-1011
- Centre Hospitalier Universitaire Vaudois
-
Luzern, Switzerland, 6000
- Kantonsspital Luzern
-
Muensterlingen, Switzerland, 8596
- Kantonsspital Muensterlingen
-
St. Gallen, Switzerland, CH-9007
- Kantonsspital - St. Gallen
-
Thun, Switzerland, 3600
- SpitalSTS AG Simmental-Thun-Saanenland
-
Winterthur, Switzerland, CH-8400
- Kantonsspital Winterthur
-
Zurich, Switzerland, CH-8091
- Universitaetsspital Zuerich
-
Zurich, Switzerland, CH-8032
- Klinik Hirslanden
-
Zürich, Switzerland, 8063
- Stadtspital Triemli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has given written informed consent before any trial specific treatment
- Histological proven diagnosis of colorectal cancer, metastatic or inoperable advanced, not amenable to curative therapy
- Measurable disease, defined as at least one lesion (outside of irradiated areas) that can be measured in at least one dimension as ≥ 10 mm (≥ 15 mm in case of lymph nodes) according to RECIST v1.1
- Tumour with wild-type KRAS and wild-type BRAF gene
- No previous systemic chemotherapy for metastatic disease (previous adjuvant chemotherapy is allowed if completed >6 months before randomization, previous rectal radio-chemo therapy if completed >1 month before randomization)
- WHO performance status 0 or 1
- Age >75 years; or: age ≥ 70 years with at least one of the following factors:
- Any functional dependence as measured by Instrumental Activities of Daily Life (IADL). Significant comorbidity according to the Cumulative Illness Rating Scale for geriatric patients (CIRS-G; any severe comorbidity > grade 3 or a total score > 5 qualifies)
- Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L
- Bilirubin ≤ 2.0 x Upper Limit of Normal (ULN) (unless known Gilbert-Meulengracht syndrome), aspartate aminotransferase (AST)<2.5xULN
- Calculated creatinine clearance ≥ 30 ml/min. (according to the formula of Cockcroft-Gault)
- Patient is able to swallow oral medication
- Baseline Quality of Life forms have been completed
Exclusion Criteria:
- Documented or suspected cerebral and/or leptomeningeal metastases (no cerebral baseline imaging required in asymptomatic patients)
- Risk of rapid deterioration due to tumor symptoms or tumor complications
- Synchronous or prior malignancy other than adequately treated non-melanomatous skin cancer or in situ carcinoma of the cervix, other malignancies unless disease free > 2 years
- Prior anti-EGFR (Epidermal Growth Factor Receptor) antibody therapy
- Severe or uncontrolled cardiovascular disease (e.g. acute coronary syndromes, cardiac failure NYHA (New York Heart Association) III or IV, clinically relevant myopathy, history of myocardial infarction within the last 12 months, significant arrhythmias)
- Concurrent severe uncontrolled medical illness (judged by the investigator) which could impair the ability of the patient to participate in the trial (e.g. uncontrolled infection, uncontrolled diabetes mellitus, active autoimmune disease)
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drug
- Definite contraindications for the use of corticosteroids or antihistamines as premedication
- Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome or history of inflammatory intestinal disease, or other disease which could alter drug absorption
- Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent, filling out QL forms, or interfering with compliance with oral drug intake
- Any concomitant drugs contraindicated for use with the trial drugs according to the Swissmedic approved product information
- Concurrent treatment with other experimental drugs or other anti-cancer therapy and/or treatment in a clinical trial within 30 days prior to randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A: Cetuximab
Cetuximab 500 mg/m2 every 2 weeks
|
Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
Other Names:
|
Active Comparator: Arm B: Cetuximab and Capecitabine
Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks * 750 mg/m2 if creatinine-clearance 30-50 ml/min |
Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
Other Names:
Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival in week 12
Time Frame: in week 12
|
A progression event is defined as (whichever occurs first):
|
in week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of life (QL)
Time Frame: Baseline, in week 7, 13 and 19
|
Baseline, in week 7, 13 and 19
|
Adverse events (CTCAE v 4.0)
Time Frame: Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until 30 days after end of treatment (estimated up to 2 years).
|
Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until 30 days after end of treatment (estimated up to 2 years).
|
Overall Response (OR)
Time Frame: Before start of treatment. In week 13 and every 12 weeks up to 2 years.
|
Before start of treatment. In week 13 and every 12 weeks up to 2 years.
|
Progression free survival (PFS)
Time Frame: PFS will be calculated sustained from randomization until documented PD or death, whichever occurs first (estimated up to 2 years).
|
PFS will be calculated sustained from randomization until documented PD or death, whichever occurs first (estimated up to 2 years).
|
Overall Survival (OS)
Time Frame: Overall survival will be calculated from randomization until death (estimated up to 2 years).
|
Overall survival will be calculated from randomization until death (estimated up to 2 years).
|
Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)
Time Frame: Until week 19.
|
Until week 19.
|
Collaborators and Investigators
Investigators
- Study Chair: Dirk Kienle, MD, Kantonsspital Graubünden
- Study Chair: Roger von Moos, MD, Kantonsspital Graubünden
- Study Chair: Ralph Winterhalder, MD, Luzerner Kantonsspital
- Study Chair: Dieter Köberle, MD, Cantonal Hospital of St. Gallen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Capecitabine
- Cetuximab
Other Study ID Numbers
- SAKK 41/10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted